Lila Sciences secured $235 million in a Series A funding round to develop its AI-powered platform aimed at accelerating drug development by integrating generative AI, robotics, and automated laboratory systems. Co-founder and CEO Geoff von Maltzahn highlighted the goal of creating 'scientific superintelligence' to massively increase the scale, speed, and intelligence of scientific research. The funding will support expansion in AI research, software, robotics, biology, chemistry, and materials science, positioning Lila at the forefront of AI-assisted innovation in life sciences.